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Immunization with mutant p53- and K-ras-derived peptides in
cancer patients: immune response and clinical outcome
Abstract
PURPOSE: To determine the ability to induce tumor-specific immunity with individual mutant K-ras-or
p53-derived peptides and to monitor clinical outcome. PATIENTS AND METHODS: Patients in
varying stages of disease underwent genetic analysis for mutations in K-ras and p53. Thirty-nine
patients were enrolled. Seventeen-mer peptides were custom synthesized to the corresponding mutation.
Baseline immunity was assessed for cytotoxic T-lymphocyte (CTL) response and interferon gamma
(IFN-gamma) release from mutant peptide-primed lymphocytes. Patients' peripheral-blood mononuclear
cells were pulsed with the corresponding peptide, irradiated, and applied intravenously. Patients were
observed for CTL, IFN-gamma, interleukin (IL) -2, IL-5, and granulocyte-macrophage
colony-stimulating factor responses, for treatment-related toxicity, and for tumor response. RESULTS:
No toxicity was observed. Ten (26%) of 38 patients had detectable CTL against mutant p53 or K-ras,
and two patients were positive for CTL at baseline. Positive IFN-gamma responses occurred in 16
patients (42%) after vaccination, whereas four patients had positive IFN-gamma reaction before
vaccination. Of 29 patients with evident disease, five experienced a period of stable disease. Favorable
prognostic markers were detectable CTL activity and a positive IFN-gamma reaction but not IL-5
release. Median survival times of 393 v 98 days for a positive versus negative CTL response (P = .04),
respectively, and of 470 v 88 days for a positive versus negative IFN-gamma response (P = .02),
respectively, were detected. CONCLUSION: Custom-made peptide vaccination is feasible without any
toxicity. CTL and cytokine responses specific to a given mutation can be induced or enhanced with
peptide vaccines. Cellular immunity to mutant p53 and K-ras oncopeptides is associated with longer
survival.
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A B S T R A C T
Purpose
To determine the ability to induce tumor-specific immunity with individual mutant K-ras– or
p53-derived peptides and to monitor clinical outcome.
Patients and Methods
Patients in varying stages of disease underwent genetic analysis for mutations in K-ras and
p53. Thirty-nine patients were enrolled. Seventeen-mer peptides were custom synthesized
to the corresponding mutation. Baseline immunity was assessed for cytotoxic T-lymphocyte
(CTL) response and interferon gamma (IFN-) release from mutant peptide-primed lympho-
cytes. Patients’ peripheral-blood mononuclear cells were pulsed with the corresponding
peptide, irradiated, and applied intravenously. Patients were observed for CTL, IFN-,
interleukin (IL) -2, IL-5, and granulocyte-macrophage colony-stimulating factor responses, for
treatment-related toxicity, and for tumor response.
Results
No toxicity was observed. Ten (26%) of 38 patients had detectable CTL against mutant p53
or K-ras, and two patients were positive for CTL at baseline. Positive IFN- responses
occurred in 16 patients (42%) after vaccination, whereas four patients had positive IFN-
reaction before vaccination. Of 29 patients with evident disease, five experienced a
period of stable disease. Favorable prognostic markers were detectable CTL activity
and a positive IFN- reaction but not IL-5 release. Median survival times of 393 v 98 days
for a positive versus negative CTL response (P  .04), respectively, and of 470 v 88 days for a
positive versus negative IFN- response (P  .02), respectively, were detected.
Conclusion
Custom-made peptide vaccination is feasible without any toxicity. CTL and cytokine
responses specific to a given mutation can be induced or enhanced with peptide vaccines.
Cellular immunity to mutant p53 and K-ras oncopeptides is associated with longer survival.
J Clin Oncol 23:5099-5107. © 2005 by American Society of Clinical Oncology
INTRODUCTION
Immunologic targeting of cancer with vac-
cines against the host’s tumors bears the po-
tential for nontoxic and specific therapy.
Molecular characterization of activated
proto-oncogenes and inactivated tumor
suppressor genes has linked these genes to
malignant progression.1 Mutations of p53
and K-ras are frequent and often result in
the generation of novel protein sequences
that are overexpressed in tumor cells bear-
ing these mutations.2-4 Novel protein se-
quences generated by point mutations
expressed intracellularly can be processed
and presented on the cell surface in the
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context of major histocompatibility complex (MHC)
class I and, thus, become accessible to cytotoxic T cells.5-8
Thus, the overexpressed mutant p53 and K-ras oncopro-
teins provide novel potential T-cell epitopes for targeting
by cellular immunity.
The host immune system involves a multitude of cell
types and mediators interacting with tumor cells. Two im-
portant populations of effector cells responsible for tu-
mor lysis are the cytotoxic T cell and the natural killer
cells. The cytotoxic lymphocyte recognizes endogenous
gene products in the context of MHC class I by the T-cell
receptor of CD8 cells. Typically, short peptide frag-
ments of endogenous proteins are found to be eight or
nine residues long and are presented on the cell surface.9
These presented peptides are generated by endogenous
antigen processing of either intracellular or membrane-
bound proteins. Oncoprotein-derived peptides from both p53
and K-ras have been shown to be processed and presented
in the context of MHC class I in tumor cells in mice8,10-12
and humans.13-17
In the present trial, we investigated the potential of
oncopeptide immunization for the purpose of immuno-
therapy in cancer patients. Immunization included a cellu-
lar vaccine with a single peptide of either p53 or K-ras
surrounding the tumor-specific point mutation character-
istic of the tumor cells. Peptides were chosen to encompass
the mutation. The peptide was loaded on peripheral-
blood mononuclear cells (PBMC) from the patient,
which functioned as antigen-presenting cells (APCs).
The present protocol represents a unique immunization
approach and establishes the ability of peptide-loaded
nonprofessional APCs to function as cellular vaccines
after irradiation in humans.
PATIENTS AND METHODS
Patient Inclusion Criteria
Patients with several types of cancers (lung, colon, breast,
ovarian, head and neck, pancreatic, esophageal, gastric, and oth-
ers) were eligible (National Cancer Institute [NCI] trial T93-
0148). Approval of the local human investigation committee and
by the Department of Health and Human Services was ascer-
tained. Patients with either evident disease and no curative option
or with no evident disease but a greater than 50% probability of
recurrence were eligible. Genetic analysis for suitable mutations in
K-ras and p53 was performed. One of the following was required:
a point mutation altering the protein sequence, a frame shift
mutation, or an insertion or deletion internal to the coding se-
quence. Eastern Cooperative Oncology Group performance status
of 0 or 1 and adequate organ functions were required. Cytotoxic
chemotherapy or corticosteroids were not allowed within 4 weeks
of the vaccination. It was not allowed to have curative option
delayed. To avoid treatment of anergic individuals, one positive
skin test for delayed hypersensitivity to a common antigen injected
intradermally (Candida, mumps, and Trichophyton) had to be
present. To make this criterion more relevant to the immunologic
end points, a positive interferon gamma (IFN-) response to
whole influenza virus infection of autologous cells was added as a
requirement for the protocol after the first seven patients. An
IFN- response of at least two-fold greater than the response in the
absence of influenza virus or a positive cytotoxic T-lymphocyte
(CTL) response to influenza was required.
Mutation Analysis of p53 and K-ras
RNA and DNA extraction was as described elsewhere.18 Mu-
tations were screened by using single-strand conformational poly-
morphism analysis on polymerase chain reaction–amplified DNA,
and the exact mutation was determined by DNA sequencing.
Peptide Synthesis and Verification
Peptides were synthesized under good laboratory practices
conditions by Peninsula Laboratories (Belmont, CA), Bachem
California (San Diego, CA), or Multiple Peptide Systems (San
Diego, CA) before shipment to the NCI for vialing. An auto-
mated synthesizer with standard solid-phase chemistry to pro-
duce peptides of 17 residues was used.
Immunization
All peptides were subjected to high-performance liquid chro-
matography analysis and sterility, pyrogen, and animal toxicity
tests. PBMC were drawn from a patient’s peripheral vein, and cells
were made devoid of RBCs by gradient centrifuging. Alternatively,
pheresis was performed to obtain 109 PBMC, and 5 108 PBMC
were pulsed with peptide; after aliquots were removed for testing,
the recovered cells were infused (usually 3 to 4 108 per dose).
Cells were pulsed with peptide at the appropriate concentration
and irradiated with 25 Gy before intravenous injection. Immu-
nization was repeated 21 days later. Repeat immunizations
were administered every 2 months for a total of four immuni-
zations or longer.
Assessment of Cellular Immune Response
To test for immunity against p53- and K-ras– derived mutant
oncopeptides, patients’ PBMC were obtained and tested for reac-
tivity in vitro. The plasma supernatant of restimulated PBMC was
collected and saved for antibody studies. For evaluating CTL and
cytokine activity in peripheral blood, PBMC were cultured in the
presence of 1 to 10 mol/L of peptide and 50 U/mL of recombi-
nant interleukin (IL) -2 (Cetus Corporation, Emoryville, CA).
Cytotoxicity against a specific peptide was assessed using autolo-
gous Epstein-Barr virus (EBV) –transformed lymphoblastoid cell
lines as target cells.19 The percent specific lysis was determined, on
triplicate samples, by the following formula: percent specific ly-
sis  (release  spontaneous release)  (maximum release 
spontaneous release) 100.
Cytokine Assays
The ability of patient PBMC to produce IL-2 to mutant
oncogene peptide was tested.20 IFN-, IL-5, and granulocyte-
macrophage colony-stimulating factor (GM-CSF) were measured
on the same culture supernatants using commercial enzyme-
linked immunosorbent assay kits (Endogen, Boston, MA for
IFN-; R&D Systems, Minneapolis, MN; and Biosource, Cama-
rillo, CA). For IL-2 response, PBMC were cultured for 7 days in the
presence or absence of patient-specific mutant oncogene peptide
and antihuman IL-2–receptor antibody, which blocks IL-2 con-
sumption (Anti-Tac, a gift of T.A. Waldmann, Bethesda, MD).
Positive control wells were stimulated with influenza A, phyto-
haemagglutinin, or allogeneic PBMC. Culture supernatants were
harvested and stored frozen until assayed for IL-2 content. The
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IL-2 assay consisted of culturing an IL-2– dependent cytotoxic
T-cell line in the presence of titrated amounts of the culture
supernatants for 42 hours with the addition of [3H]thymidine for
the last 18 hours. The wells were harvested, and the amount of 3H
incorporation was measured with a liquid scintillation counter.
After subtraction of background counts (counts from superna-
tants of unstimulated PBMCs), the amount of IL-2 produced by
patient PBMC was compared with a standard curve generated with
a known amount of recombinant human IL-2. PBMC were also
used to determine immunity against influenza. Patients were eli-
gible for vaccination if the IFN levels were  two-fold compared
with similar cultures without influenza.
Definition of Immunologic Response
Patients were considered to have had a positive immune
response if either of the following two conditions were met: cyto-
toxic T-cell response was positive and there was detectable
preimmunization-specific killing or a 1.5-fold increase com-
pared with the preimmunization percent killing was observed.
If there was no detectable preimmunization-specific lysis, a
postimmunization-specific lysis of  10% compared with back-
ground (peptide v no peptide; a widely used threshold for positiv-
ity) was considered a positive response only if specific lysis of
targets pulsed with peptide was also statistically different from the
lysis of cells without peptide using the Student’s t test. A cytokine
response was scored positive (IFN-, IL-2, and IL-5) if there was
detectable ( 50 pg/mL) preimmunization peptide-specific cyto-
kine response and a  two-fold increase over the preimmuniza-
tion response was detected. If there was no detectable
preimmunization response, a postimmunization response was
considered a positive response if this value was at least two-fold
greater than the no-peptide control, greater than 50 pg/mL, and
significantly different from the no-peptide control using the Stu-
dent’s t test.
Statistical Analysis
In case of CTL detection, a statistical difference test (paired
Student’s t test) was used. Fisher’s exact test was used where
appropriate. Survival data analysis was performed using the
Kaplan-Meier method, and a log-rank test was performed. Statis-
tical significance was considered as P .05. Stepwise multiple Cox
regression analysis was performed for multivariate analysis. For
survival analysis, patients with baseline or positive results after
vaccination were scored.
RESULTS
Two hundred seventy-six patients were enrolled onto the
screening. Reasons for not receiving vaccination were lack
of a suitable mutation and progression of disease. Of the
screened patients, 39 patients (14%) were eligible and en-
tered onto the study and received at least one immuniza-
tion. Of the 38 immunologically valuable patients (Table 1),
20 (56%) received fewer than the four baseline vaccinations
planned. This was a result of progression of disease among
the patients with advanced malignancies. Six patients with-
out progressive or recurrent disease and with positive im-
mune responses to vaccinations were elected to receive
additional maintenance vaccinations. No toxicity, acute or
delayed, was attributed to vaccination. Follow-up was until
death, with a mean follow-up time of 280 days (ranging
until 580 days) for patients vaccinated with evident disease
and a mean of 380 days (ranging until 5 years) after adju-
vant immunization. Patient symptoms and/or deteriora-
tion were attributed to the underlying cancer.
Immunologic Responses
Immunologic responses are listed in Table 2. Of 39
patients who received one or more immunizations, 38 pa-
tients underwent analysis. One patient progressed rapidly
and died soon after one vaccination.
Detectable cellular immunity against mutant p53 or
K-ras, as determined by either peptide-specific cytokine
release of IFN- (chosen because it is the cytokine most
widely used as an indication of a CD8 T-cell response) or
peptide-specific cellular cytotoxicity, was more likely to be
found in patients treated adjuvantly than in patients with
evident disease. Detection of positive CTL occurred in four
of nine patients in the adjuvant setting and in six of 28
patients with evident disease (P  .2). A positive IFN-
reaction was observed in eight of nine patients treated ad-
juvantly and in eight of 28 patients treated with evident
disease (P .002). Of the 35 patients undergoing immuno-
logic assessment for influenza, 25 had responses, seven were
not tested, and three (placed on the study early) tested nega-
tive. Immunity against a recall antigen from influenza was
comparable in patients immunized adjuvantly (eight of eight
patients) or with evident disease (17 of 20 patients; P .5).
Ten patients (26%) had a CTL response to mutant
peptide on at least one occasion; an example is shown in
Figure 1A. Two patients (6%) had CTL responses to mutant
peptide at baseline before immunization (patients UT [The
University of Texas] 33 and NCI 89; Table 1). Both patients
had a further positive CTL response to vaccination as indi-
cated by an increase in CTL compared with the initial
positive response. Six of 10 patients had positive CTL re-
sponses on more than one occasion. Concanavalin A blasts
were used as autologous targets for patients NCI 90, NCI 94,
UT 26, UT 116, UT 132, and UT 143 (Table 1) because no EBV
blasts could be generated. Three of these six patients had at
least one positive CTL assay. The remainder of the patients had
EBV-transformed lymphocytes used as autologous targets.
Positive responses to IFN-  by stimulation index cri-
teria occurred in a total of 17 patients (45%) before and
after vaccination and 16 patients (42%) after vaccination.
An example is show in Figure 1B. Five patients (13%) had
positive IFN- assays before vaccination (patients NCI 35,
UT 33, NCI 37, UT 117, and NCI 90). Two of these five
patients (UT 33 and NCI 90) had significant increases over
their baseline positive responses, indicating a positive re-
sponse to vaccination. Three patients had decreases from
baseline positive responses (NCI 35, NCI 37, and UT 117).
Assays for IL-2, IL-5, and GM-CSF were also performed,
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with intermittent positive results using stimulation index
criteria, both before and after vaccination. Six (18%) of the
34 patients who were tested had a positive IL-5 assay at
baseline, with 11 (32%) of 34 patients having positive post-
vaccination assays. Assays for IL-2 were performed on only
six patients, with two patients having positive assays before
vaccination and two different patients having positive as-
says after vaccination. Assays for GM-CSF release were per-
formed on only 13 patients, with one patient having a
positive assay at baseline with no subsequent positive re-
sponse and five patients (38%) having new positive re-
sponses after vaccination.
One patient who had evidence of cytokine response to
mutant peptides was also tested for response to corresponding
wild-type peptides. Figure 1C shows this patient’s PBMCs with
significantly increased IFN- production when exposed to
influenza and to mutant p53 peptide but not when exposed to
wild-type p53. Comparison assays between mutant and wild-
type controls are not available for other patients.
Clinical Outcome
The median survival was 115 days (range, 26 to 685
days). Of 29 patients with evident disease, 24 progressed,
and five had periods of stable disease (range, 4 to 40
Table 1. Patient Characteristics
Patient No. Age (years) Sex Disease AJCC Stage No. of Vaccinations Point Mutation
K-ras evident
NCI 2 48 M Lung IV 3 K-ras 12 Gly to Val
NCI 4 60 M Colon IV 4 K-ras 12 Gly to Ser
NCI 18 61 F Colon IV 2 K-ras 12 Gly to Asp
NCI 35 44 M Lung IV 3 K-ras 12 Gly to Val
UT 1 66 M Pancreas IV 2 K-ras 12 Gly to Val
UT 14 63 F Pancreas IV 2 K-ras 12 Gly to Arg
UT 23 70 F Lung IV 4 K-ras 12 Gly to Asp
UT 33 65 M Pancreas IV 2 K-ras 12 Gly to Val
UT 39 73 M Pancreas IV 1 K-ras 12 Gly to Arg
UT 46 69 M Pancreas IV 2 K-ras 12 Gly to Asp
UT 54 66 F Pancreas IV 2 K-ras 12 Gly to Asp
UT 58 49 M Pancreas IV 2 K-ras 12 Gly to Asp
UT 63 68 M Pancreas IV 2 K-ras 12 Gly to Asp
VU 1 54 F Lung IV 4 K-ras 12 Gly to Asp
VU 3 62 F Lung IV 4 K-ras 12 Gly to Val
UT 71 48 M Colon IV 4 K-ras 12 Gly to Asp
NCI 46 63 M Colon IV 1 K-ras 12 Gly to Cys
NCI 63 68 M Lung IV 9 K-ras 12 Gly to Cys
K-ras adjuvant
UT 22 64 M Colon III 5 K-ras 12 Gly to Asp
NCI 94 65 M Pancreas II 3 K-ras 12 Gly to Asp
UT 89 57 F Colon II 24 K-ras 13 Gly to Asp
p53 evident
NCI 7 56 M Colon IV 1 p53 152 Pro to Leu
NCI 16 69 M Colon IV 1 p53 273 Arg to Cys
UT 40 66 M Lung IV 4 p53 220 Tyr to Cys
UT 78 57 F Breast IV 4 p53 273 Arg to Cys
NCI 37 56 M Lung IV 2 p53 246 Met to Val
NCI 48 41 F Lung IV 4 p53 254 Ile to Asn
NCI 95 53 M Colon IV 4 p53 245 Gly to Ser
NCI 116 57 M Colon IV 2 p53 282 Arg to Trp
UT 117 61 M Colon IV 3 p53 249 Arg to Met
UT 156 59 F Ovarian IV 2 p53 248 Arg to Gln
VU 6 65 M Colon IV 1 p53 228 del2bp
p53 adjuvant
UT 26 55 F Colon III 4 p53 157 Val to Phe
NCI 55 47 M Head and neck II 8 p53 143 Val to Glu
NCI 90 55 F Lung II 6 p53 159 Ala to Pro
UT 132 52 F Breast II 4 p53 176 Cys to Ser
UT 143 61 F Colon II 5 p53 245 Gly to Ser
VU 7 63 F Breast II 4 p53 237 Met to Ile
Abbreviations: AJCC, American Joint Comittee on Cancer; NCI, National Cancer Institute; UT, The University of Texas; VU, Vanderbilt University; M, male;
F, female; Gly, glycine; Val, valine; Ser, serine; Arg, arginine; Asp, aspartic acid; Cys, cysteine; Pro, proline; Leu, leucine; Tyr, tyrosine; Met, methionine; Ile,
isoleucine; Asn, asparagine; Trp, tryptophan; Gln, glutamine; Phe, phenylalanine; Glu, glutamic acid; Ala, alanine.
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CTL Activity in Presence






NCI 2 Neg Neg Neg
NCI 4 Neg Neg 3.9, week 22
NCI 18 Neg Neg Neg
NCI 35 Pos week 3 42:1 20 3 3.9, week 11
UT 1 Neg Neg Neg
UT 14 Neg Neg Neg
UT 23 Neg Neg Neg
UT 33 Pos week 3 55:1 24 0 4.9, week 3
UT 39 Neg Neg Neg
UT 46 Neg Neg Neg
UT 54 Neg Neg Neg
UT 58 Neg Neg Neg
UT 63 Neg Neg Neg
VU 1 Neg Neg Neg
VI 3 Neg Neg Neg
UT 71 Pos week 30 25:1 19 7 6.0, week 35
NCI 46 Neg Neg Neg
NCI 63 Pos week 3 120:1 67 6 4.8, week 3
12 100:1 51 4
68 244:1 19 9
70 9:1 19 8
K-ras adjuvant
UT 22 Neg Neg 2.7, week 22
NCI 94 Neg Neg 2.3, week 3
UT 89 Pos week 14 400:1 25 5 10.2, week 91
23 400:1 15 1
58 6:1 57 38
59 22:1 22 0
64 51:1 66 40
67 69:1 28 1
82 9:1 36 18
84 71:1 33 7
p53 evident
NCI 7 Neg Neg Neg
NCI 16 Neg Neg Neg
UT 40 Neg Neg Neg
UT 78 Neg Neg Neg
NCI 37 Neg Neg Neg
NCI 48 Pos week 3 44:1 27 11
11 29:1 24 9 3.4, week 11
NCI 95 Neg Neg 2.4, week 22
NCI 116 Neg Neg Neg
UT 117 Pos week 6 76:1 23 3
11 55:1 32 16 2.7, week 11
UT 156 Neg Neg Neg
VU 6 NA NA NA
p53 adjuvant
UT 26 Pos week 19 136:1 14 3 67.0, week 47
56 170:1 20 5
NCI 55 Neg Neg 6.6, week 11
3.6, week 22
4.3, week 46
NCI 90 Pos week 3 24:1 18 2 2.6, week 3
12 204:1 16 6 5.1, week 12
14 200:1 20 5 2.0, week 14
30 13:1 15 5 2.6, week 22
2.0, week 38
5.6, week 55
UT 132 Neg Neg 2.0, week 2
3.3, week 11
UT 143 Neg Neg 2.2, week 31
VU 7 Pos week 3 20:1 30 19 Neg
Abbreviations: CTL, cytotoxic T lymphocyte; IFN-, interferon gamma; SI, stimulation index; NCI, National Cancer Institute; UT, The University of Texas; VU,
Vanderbilt University; Neg, negative; Pos, positive; NA, not applicable.
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months). Of the nine patients treated adjuvantly, three
patients relapsed (with one death), whereas the other six
patients remain without evidence of disease. Overall, there
was no statistically significant association between success-
ful induction of immunity against K-ras or p53 peptides by
means of strength or quality of the immune response and
clinical outcome. Notably, one patient (UT 89) with meta-
static colon cancer who was without evidence of disease
after resection of a metastatic lesion in the lung continued
to be in remission nearly 5 years after resection. This patient
has had multiple positive CTL responses. Only one of the
five patients having periods of stable disease after vaccina-
tion had more than one positive CTL response.
Univariate Analysis
The median survival of patients with evident disease
was 115 days (range, 26 to 685 days). Survival was similar
for male and female patients. There was no association of
survival with age. Patients immunized with mutant K-ras or
p53 peptide had similar outcomes (Fig 2A). No survival
benefit was detected in patients with positive CTL or IFN-
responses to influenza virus. Prolonged survival was associ-
ated with positive CTL detected against mutant p53 or
mutant K-ras. The median survival increased from 98 to
393 days (P  .038; Fig 2B). A positive IFN- release of
PBMC to stimulation with mutant peptide was associated
with an increased median survival from 88 to 470 days
Fig 1. Peptide-specific immune responses. (A) Cytotoxic T-lymphocyte
(CTL) response in patient NCI 63 to K-ras 12-Cys peptide PR18. (B)
Interferon gamma (INF-) response to mutant K-ras by autologous mononu-
clear cells in patient NCI 4 over time after repeated immunization. (C)
Postvaccination INF- production responses to mutant but not wild-type
p53-derived peptide in patient NCI 55. E:T ratio, effector (CTL) to target
(Epstein-Barr virus lymphoblastoid cells); PR17, p53 peptide.
Fig 2. Survival of patients with evident disease. (A) PEP 1 indicates
immunization with K-ras; PEP 2 indicates immunization with mutant p53
peptides. (B) Survival and cytotoxic T-lymphocyte (CTL) activity. CTL 0, no
cellular immunity; CTL  1, positive cellular toxicity (P  .038). (C) Survival
and interferon gamma (IFN-) response. INFG  0, no IFN- release after in
vitro stimulation; INFG  1, positive IFN- release (P  .017).
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(P .017; Fig 2C). However, there was no association of a
positive IL-5 stimulation response to mutant peptide with
survival (P .2).
A total of 19 vaccine doses were administered to the
nine patients with evident pancreatic carcinoma (an aver-
age of 2.1 vaccines per patient). One patient mounted a
positive cellular immune response. Nine patients presented
with non–small-cell lung cancer and evident disease and
received a total of 35 vaccine doses (an average of 3.9 vac-
cines per patient). Colorectal adenocarcinoma was diag-
nosed in 10 patients with evident disease, and a total of 24
vaccines were applied (an average of 2.4 vaccines per pa-
tient). The study protocol requiring four vaccines was not
feasible for the majority of the patients with evident disease.
In terms of the diagnosis, the median survival ranged from
60 days for pancreatic cancer to 207 days for colorectal
cancer and 230 days for non–small-cell lung cancer; but
overall, the differences were not significant (P .15).
To investigate an association between number of im-
munizations with survival, patients who were immunized
only once were compared with patients who received at
least two vaccinations. There was no association between
amount of immunization and survival. To exclude patients
with bad prognosis independent of vaccine doses adminis-
tered, we looked for a possible association between the
number of immunizations and the immunologic response
rate. Analysis was repeated on only those patients who
survived at least 45 days after the first immunization. Again,
a survival benefit was visible for patients with a positive
IFN- response to mutant peptide.
Multivariate Analysis
Stepwise regression was performed to avoid more than
two factors being tested simultaneously. Sex, age, type of
cancer, and positive or negative immunity to influenza,
number of vaccine doses administered, a positive CTL re-
action, and IL-5 and IFN-  responses were inspected in the
multivariate analysis. A positive CTL reaction was associ-
ated with a positive IFN- response to mutant peptide. Sex
became a prognostic marker mainly because male patients
who did not show any positive IFN- response to mutant
peptide revealed a reduced median survival (P  .002). A
positive IFN- response to mutant peptide was a prognosti-
cally independent favorable parameter for survival (P .004).
DISCUSSION
This trial was performed to assess the feasibility of individ-
ualized oncopeptide vaccines in patients. Immunization
with a cellular vaccine consisting of mutant p53- and K-ras–
derived peptide-pulsed irradiated PBMC is immunogenic
in cancer patients without any evidence for autoimmune
reactions. Several aspects of the trial design are worth no-
ticing. First, only a single T-cell epitope is used for immu-
nization purposes. Second, the peptides that were used have
a low intrinsic immunogenicity. Third, several patients with
evident disease were able to mount a measurable cellular
immune response to mutant oncopeptides. No attempts
were made to analyze the peptides for potential matching of
binding motifs of the mutant peptides to MHC class I, and
their ability to induce T help is unknown.21
In the present trial, the vaccine consisted of irradiated
PBMC pulsed with the epitope of interest. Whether irradi-
ated PBMC in humans can act as APCs by themselves is
unknown. Previous studies in murine systems established
the need for irradiation unless a pure population of profes-
sional APCs is used.22 Irradiated APCs survive for a shorter
time after intravenous injection and, thus, get cleared more
readily.23 Peptides presented in the context of MHC class I
are processed by the host APCs and become accessible for
immune response induction.24,25 To what extent this im-
munization protocol could be improved (for example, by
using professional APCs such as dendritic cells) remains
debatable.26 To achieve better immunization efficacy, vari-
ous strategies have been proposed.27-31 However, any effi-
cient immune induction works through optimal antigen
presentation to effector cells, which is always accomplished
by dendritic or other efficient professional APCs. Direct
manipulation of professional APCs to ensure optimal pre-
sentation or indirect antigen presentation through mole-
cules, dendritic cell– derived exosomes, or cellular vaccines
may equally lead to sufficient immune reaction. Injection of
the vaccine into lymph nodes could potentially be more
efficient because the antigens become quickly available to
professional APC. Because the aim is a strong cellular im-
mune response that will assure successful immunologic
targeting, the use of a highly immunogenic antigen may be
more important than the method of immunization. Cancer
antigens should preferentially have a high intrinsic immu-
nogenicity for both T-help and cytotoxic T-cell epitopes
and be easily accessible to effector cells. A potentially more
appealing circumstance for cancer vaccines would be im-
munization against non– host-derived viral epitopes asso-
ciated with human cancer, such as in cervical cancer.32 A
peptide vaccine of the E7 viral protein showed no evidence
for toxicity and some response in two of 19 patients.33
The present data confirm reports of pre-existing cellu-
lar immunity in cancer patients against defined oncopep-
tides.34 In the present trial, positive cellular immunity was
induced in all nine patients treated adjuvantly. Evident
cancer may impact on the immune function of a host, and
thus, it is not surprising to observe less efficient immune
induction in patients with a significant tumor load.35 There
are many strategies tumor cells use to evade the immune
response. However, most tumors that are clinically relevant
remain ignored by the immune system or have evolved
strategies to suppress effective immune responses.36-40
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Strategies improving sustained accessibility of the tumor
cells to the immune system may be at least as important as
the target epitope.
The present study confirms the immunogenicity of
K-ras– derived peptides in cancer patients. Other research-
ers have shown successful immune induction against mu-
tant K-ras peptide when treating pancreatic carcinoma
patients, suggesting prolonged survival of vaccine respond-
ers.41 Compared with our trial, the immunization protocol
differed, and intradermal injections of peptides with GM-
CSF as an adjuvant were used. The immunologic testing for
immune response was based on the T-cell [3H]thymidine
uptake, a readout that does not determine cytotoxicity, that
we measured in the present trial. In this study, patients with
pancreatic cancer, all with K-ras mutations, did not react to
the immunization, except for one patient. The impaired
median survival and the inability to apply more than two
vaccines per pancreas cancer patient might have biased the
survival analysis, and the worse prognosis of pancreatic
cancer patients could partly be responsible for the worse
outcome and not the absence of immune response per se.
Whether the ability to mount a cellular immune
response against a mutant oncopeptide is directly responsi-
ble or indirectly linked to better outcome in vaccine-
responding patients in the present trial is not clear.
Excluding patients with rapidly progressive disease who
died within 45 days after the first immunization did not
alter the results. An association of antitumor immunity
with reduced progression of metastasis has been reported
for melanoma.42 In melanoma patients, successful induc-
tion of immunity has been shown to improve outcome in a
randomized adjuvant setting.43-46 In patients with colorec-
tal cancer, vaccine trials have been conducted but have been
mostly limited to the adjuvant setting.47-49 In patients with
metastatic disease, vaccination has not been shown to im-
prove outcome,50 although one trial suggested that positive
immunity was associated with slower disease progression.51
One of the remarkable features of the present study is
that a minority of 14% of patients screened for mutant p53
and K-ras were eligible for specific immunization. This
situation makes a broad clinical approach difficult, espe-
cially in the context of custom-made peptide immuniza-
tion. The effort to screen many patients to obtain a selected
population is only cost effective if there is a high probability
of successful intervention outcome or if the patient selec-
tion result is a spin-off of other screening. The fraction of
eligible patients could be increased with automatic se-
quencing and peptide synthesis processes if additional mu-
tant proteins were used or if patients with earlier stage
disease were eligible. To date, none of the tumor vaccines
for cancer have yielded high response rates in any disease to
justify screening for rare defined epitopes.
Both significant immunity to tumor-specific peptide
antigens in human cancer patients and an association be-
tween positive immune responses and prognosis were ob-
served. To what extent the association between immunity
and survival is a direct consequence of the vaccinations
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